Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- AbbVie Japan Files Skyrizi for Palmoplantar Pustulosis
July 1, 2022
- Blood Cancer Drug Pegaspargase Filed in Japan: Nihon Servier
July 1, 2022
- Sanofi Seeks Dupixent Label Expansion for Prurigo Nodularis in Japan
July 1, 2022
- 37 Pharma Execs Get 100 Million-Plus Yen in FY2021, Top 3 at Takeda: Securities Reports
July 1, 2022
- Despite 4 Trillion Yen Debt, Takeda CEO Confident in Deleveraging, Pipeline Boost, Shareholder Returns
June 30, 2022
- Pfizer Seeks Japan Approval of Aplastic Anemia Med
June 30, 2022
- Tissue-Engineering Market in Asia to Hit 712 Billion Yen in 2030: Fuji Keizai
June 30, 2022
- Takeda CEO’s Pay Down to 1.86 Billion Yen in FY2021
June 30, 2022
- Wholesalers Bear Over 50 Billion Yen in Annual Costs Tied to Restricted Drug Supply: Crecon Estimate
June 29, 2022
- Astellas/Sutro to Codevelop Next-Gen Immunostimulatory ADCs for Cold Tumors
June 29, 2022
- Solasia, Nippon Kayaku Forge Capital and Business Tie-Up
June 29, 2022
- Ono Expands CAR-T Collaboration with Fate Therapeutics
June 29, 2022
- Shingrix Filed in Japan for At-Risk Adults aged 18 and Older: GSK
June 29, 2022
- Brexpiprazole Cuts Alzheimer’s Agitation in PIII Study: Otsuka/Lundbeck
June 28, 2022
- Astellas’ Pompe Gene Therapy Trial Hit with FDA Clinical Hold
June 28, 2022
- Enhertu Filed for HER2 Low Breast Cancer in Japan: Daiichi Sankyo
June 28, 2022
- Novo Japan Seeks Thumbs-Up for Sogroya Use in Short Stature
June 28, 2022
- Mitsubishi Tanabe, EditForce Join Forces for Discovery of Gene Therapy in CNS
June 28, 2022
- Kyowa Kirin Gets EU Backing for Crysvita’s Label Expansion into TIO
June 28, 2022
- Kobayashi Kako to Withdraw Marketing License Next April
June 28, 2022
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…